INTEGRITY: Our approach is scientific. We are dedicated to our task and never cut corners. Those who need us the most rely on our precision. We always deliver the highest quality. Because we know that trust is earned, and without it we are nothing.
COLLEGIAL: We work together as a team to enhance each other’s strengths, and we keep our partners close. Everyone has equal input. We share information to keep our stakeholders updated on our progress so that we can tackle challenges together and share our victories.
BRAVERY: Exploring new technologies, without certain knowledge of whether it will succeed, takes courage. So does doing things differently. Believing in change. Pushing boundaries and daring to be innovative. For us, it is all or nothing. We have set out to change respiratory medicine. That is our passion.
.png)
We lead responsibly and prioritize the highest quality standards for more transparent, ethical, and resilient operations — from governance and workforce to human rights and supply chain responsibility. In all we do, we hold ourselves accountable to higher governance standards for our people and the planet.
The company has operations in Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, China, and the United States.
We aim to create smart solutions improving life, work and society. This is what makes us both fearless, playful and responsible
By combining strong professionals and creative innovators in our own framework for development, we make our customers better and more profitable.
Is a health technology cluster, dedicated to accelerating and supporting the development of new medtech, eHealth products, services and innovative solutions for the Norwegian and global health care market.
RESPINOR was ranked number 1st of 237 applications in the Horizon 2020 phase II SME instrument call. The company will use the EU funding to develop a market ready product and to conduct a randomised clinical trial to obtain clinical evidence of its use in the weaning process.
Horizon 2020 is the biggest EU Research and Innovation programme with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries, and world-firsts by taking great ideas from the lab to the market.
.jpg){kind=icon}
RESPINOR was awarded funding for 2017 from FORNY 2020 to perform activities bringing the company to clinical and technical verification.
FORNY2020 aims at creating value and benefits for society from research results. This is done by funding the Norwegian technology transfer offices (TTOs) and projects in need of proof-of-concept
RESPINOR was awarded research grants for clinical evidence studies during 2021 and 2022.
RESPINOR was awarded seed funding from Inven2. Through this investment, Inven2 became the third largest shareholder in RESPINOR.
Inven2 is owned by the University of Oslo and Oslo University Hospital and aims to support the commercialization of Norwegian innovations.
RESPINOR was awarded funding from Innovation Norway for exploring market opportunities and the commercial potential of our product idea. The support was of great help to the company in the early phase of development.
Innovation Norway is the Norwegian Government’s most important instrument for innovation and development of Norwegian enterprises and industry. We support companies in developing their competitive advantage and enhancing innovation.
RESPINOR (in collaboration with K8 Industrial Design) was awarded funding from Design and Architecture Norway (DOGA) as part of their Design-driven Innovation Program (DIP).
Under this program, DOGA aims to facilitate the involvement of designers during the idea phase of innovation projects so that final products have a greater chance of meeting the needs of the user.
RESPINOR ranked 3rd of 323 applicants for Eurostars funding. This funding was used to support the development of the prototype device.
Eurostars is a joint program between EUREKA and the European Commission for SMEs to foster international collaboration to support the rapid development of innovative projects.
“I think it gives us a very quick and easy way to determine if a patient has a chance at successful extubation.”
RESPINOR: MedTech innovator specializing in diaphragm monitoring, introducing DXT, a non-invasive ultrasound-based technology to improve critical care and outcomes.